
Neurologist

No OPD information available
Cerebelloolivary Atrophy
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy
Drug Induced Dyskinesia
Dysgraphia
Movement Disorders
Parkinson's Disease
CACH Syndrome
Chiari Malformation
Chiari Malformation Type 2
Chorea
Dementia
Dysarthria
Encephalitis
Essential Tremor
Focal Dystonia
Huntington Disease
Neurotoxicity Syndromes
Pseudotumor Cerebri Syndrome
Tardive Dyskinesia
Torticollis
Vasoconstriction
Peter A. Kempster is a male medical professional who helps people with different brain and movement problems like Parkinson's Disease, Chorea, and Dementia. He also treats conditions such as Dysgraphia, Encephalitis, and Torticollis. Peter Kempster is skilled in understanding and managing these health issues.
Peter A. Kempster talks to his patients in a caring and respectful way, making them feel comfortable and safe. Patients trust him because he listens to their concerns and explains things clearly. He shows empathy and kindness, which helps patients feel supported during their treatment.
Peter A. Kempster stays updated with the latest medical knowledge by reading research papers and attending conferences. This helps him provide the best care for his patients. He works closely with other medical professionals to share ideas and learn from each other. This teamwork ensures that patients receive comprehensive and effective treatment.
Peter A. Kempster's work has made a positive impact on many patients' lives. His research on Parkinson's Disease has helped doctors understand how the disease progresses, leading to better treatment options. He has also been involved in clinical trials to find new ways to treat conditions like Huntington's Disease, showing his dedication to improving patient outcomes.
One of Peter A. Kempster's notable publications is a study on the rate of motor progression in Parkinson's Disease, which was published in a respected medical journal. He has also been involved in clinical trials to test new treatments for Huntington's Disease. Though one trial was terminated, his commitment to finding innovative solutions for patients remains strong.
Enrollment Status: Terminated
Published: April 25, 2022
Intervention Type: Drug
Study Drug: WVE-120102
Study Phase: Phase 1/Phase 2
